15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering VistaGen Therapeutics Inc, 0 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $0.90 to $0.90, so the covering firms are broadly aligned. The average target of $0.90 sits 242% above the current $0.26. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.36 next quarter toward $-1.54 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Hold
Strong Buy00%
Buy00%
Hold3100%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to VistaGen Therapeutics Inc.
As of Aug, 0 of 3 firms rate VTGN a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VTGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.36
Range $-0.36 – $-0.36 · 1 analysts · -20% YoY
Next period, 1 analysts expect VistaGen Therapeutics Inc to earn $-0.36 a share (range $-0.36 – $-0.36), versus $-0.45 a year earlier. Full-year consensus is $-1.45, growing to $-1.54 the year after.
REVENUE · NEXT QUARTER
$166.7K
Range $0 – $500.0K · 1 analysts · -45% YoY
Revenue is expected to reach $166.7K (range $0 – $500.0K), -45.0% year-over-year. Full-year consensus is $1.1M, rising to $0 next year.
Top analysts covering VistaGen Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VTGN.
#1
Jason McCarthy
Maxim Group · Rank #417
Hold
No targeton VTGN
Overall win rate
33%
+ Follow
#2
Andrew Tsai
Jefferies
Hold
$0.90+241.6% to target
Coverage
—
+ Follow
#3
Elemer Piros
Lucid Capital
Hold
$1.00+279.5% to target
Coverage
—
+ Follow
#4
TL
Tim Lugo
William Blair
Hold
No targeton VTGN
Coverage
—
+ Follow
VTGN stock forecast FAQ
What is VTGN's average 12-month price target?+
The 1 analysts with a live target average $0.90 for VistaGen Therapeutics Inc over the next 12 months, ranging from a $0.90 high to a $0.90 low.
Is VTGN stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 3 analyst ratings, 0 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover VTGN?+
3 analysts have an active rating on VistaGen Therapeutics Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering VTGN?+
Among analysts who currently cover VTGN, Jason McCarthy of Maxim Group has the strongest overall Quantellect track record (Rank #417). Their current call is Hold.
What is VistaGen Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.36 per share (range $-0.36 – $-0.36) across 1 analysts. Full-year EPS is projected at $-1.45, rising to $-1.54 the following year.
How much revenue is VistaGen Therapeutics Inc expected to report next quarter?+
Consensus revenue is $166.7K (range $0 – $500.0K). Full-year revenue is projected at $1.1M, growing to $0 next year.
Have analysts been upgrading or downgrading VTGN lately?+
As of Aug, 0 of 3 firms rate VTGN a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VTGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
